Skip to main content

BRIEF RESEARCH REPORT article

Front. Immunol.
Sec. T Cell Biology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1470546

IL-33-primed human mast cells drive IL-9 production by CD4 + effector T cells in an OX40L dependent manner

Provisionally accepted
  • 1 INSERM U1220 Institut de Recherche en Santé Digestive, Toulouse, France
  • 2 Université Toulouse III Paul Sabatier, Toulouse, Occitanie, France
  • 3 INSERM U1037 Centre de Recherche en Cancérologie de Toulouse, Toulouse, Midi-Pyrénées, France

The final, formatted version of the article will be published soon.

    is an alarmin released by epithelial cells in response to tissue damage. It activates resident immune sentinel cells, which then produce signals commonly associated with type 2 immune responses, particularly affecting infiltrating antigen-specific T cells. Given that mast cells (MCs) are a primary target of IL-33 and can shape T helper (Th) cell responses, we investigated the effect of IL-33 priming on the ability of MCs to influence Th cell cytokine production. To examine the Th cell/MC interaction, we developed human primary MC/memory CD4 + T cell coculture systems involving both cognate and non-cognate interactions. Our results demonstrated that IL-33-primed MCs, whether as bystander cells cocultured with activated effector T cells or functioning as antigenpresenting cells, promoted IL-9 and increased IL-13 production in Th cells via an OX40L-dependent mechanism. This indicates that MCs sense IL-33-associated danger, prompting them to direct Th cells to produce the key type 2 effector cytokines IL-9 and IL-13.with Th cells and influence their polarization. We showed that IL-33-primed MCs fostered Th2 cell responses and let emerge IL-9 producing Th cells in an OX40L-dependent manner.provide cues required by infiltrated Th cells to produce their cytokines and also signals that mold the panel of produced cytokine, here IL-9 and IL-13 via OX40-OX40L interaction.The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

    Keywords: mast cell, IL-33, OX40L, Th cell, IL-9

    Received: 25 Jul 2024; Accepted: 05 Sep 2024.

    Copyright: © 2024 Espinosa, Battut, Leveque, Valitutti, Cenac and DIETRICH. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Eric Espinosa, INSERM U1220 Institut de Recherche en Santé Digestive, Toulouse, 31024, France

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.